2-(4-bromo-phenyl)-4,5-bis-(4-methoxy-phenyl)-1H-imidazole | 36741-04-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-bromo-phenyl)-4,5-bis-(4-methoxy-phenyl)-1H-imidazole
• 英文别名: 2-(4-bromophenyl)-4,5-bis(4-methoxyphenyl)-1H-imidazole
• CAS: 36741-04-5
• 化学式: C₂₃H₁₉BrN₂O₂
• 分子量: 435.32
• InChiKey: BXVBOGMTNIOMQA-UHFFFAOYSA-N

物化性质

• 沸点：
  593.7±50.0 °C(Predicted)
• 密度：
  1.356±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  47.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-bromo-phenyl)-4,5-bis-(4-methoxy-phenyl)-1H-imidazole 、 3-溴丙烯 在 sodium hydroxide 、 C₆H₅CH=C[CH₂N⁽¹⁺⁾Et₃Br^(1-)]2 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 1-allyl-2-(4'bromophenyl)-4,5-bis(p-methoxyphenyl) imidazole
  参考文献：
  名称：

  在 PTC 条件下使用新的相转移试剂对 2,4,5-三苯基咪唑衍生物进行 N-烷基化

  摘要：

  相转移催化 2,4,5-三苯基咪唑衍生物的 N-烷基化反应，使用一种新的相转移试剂，即 2-benzilidine-N,N,N,N',N',N'-hexaethyl propane-1,3 -二溴化二铵已被描述。所有 14 种化合物的结构均已通过光谱方法确定。

  DOI：

  10.1081/scc-100105320
• 作为产物：
  描述：

  对溴苯甲醛 、 4,4'-二甲氧基苯酚酯 在 四氢化物钛 、 ammonium acetate 作用下， 以 甲苯 为溶剂， 反应 11.0h， 以15%的产率得到2-(4-bromo-phenyl)-4,5-bis-(4-methoxy-phenyl)-1H-imidazole
  参考文献：
  名称：

  分子筛负载钛催化剂在温和碱性条件下一锅法三组分合成 2,4,5-三芳基-1H-咪唑

  摘要：

  通过 1,2-二羰基化合物、苯甲醛和醋酸铵在 4A 分子筛的存在下，通过一锅缩合反应合成了一系列 2,4,5-三取代的咪唑，收率良好至极好。钛（IV）作为一种高效的多相催化剂。催化剂可以很容易地回收和重复使用，而不会显着损失活性。

  DOI：

  10.1055/s-0037-1611155

文献信息

• Magnetically separable and recyclable g-C3N4 nanocomposite catalyzed one-pot synthesis of substituted imidazoles
  作者：Tahereh Soleymani Ahooie、Najmedin Azizi、Issa Yavari、Mohammad Mahmoudi Hashemi

  DOI：10.1007/s13738-017-1284-9

  日期：2018.4

  A green, reliable synthetic method and highly efficient one-pot three-component synthesis of 2,4,5-trisubstituted imidazoles from 1,2-diketones, aldehydes and ammonium acetate in the presence of recyclable magnetic graphitic carbon nitride nanocomposite (Fe3O4@g-C3N4) has been developed. Various imidazole derivatives were obtained in moderate to excellent yields and high purity after recrystallization

  在可循环使用的磁性石墨氮化碳纳米复合材料（Fe 3 O）存在下，绿色，可靠的合成方法和高效的一锅三组分合成法，由1,2-二酮，醛和乙酸铵合成2,4,5-三取代的咪唑4 @gC 3 N 4）已经被开发出来。从乙醇中重结晶后，以中等至极好的收率和高纯度获得了各种咪唑衍生物。有趣的是，低成本的Fe 3 O 4 @gC 3 N 4 一种无毒且价格低廉的催化剂，即使使用十个循环后，使用外磁体仍具有出色的可回收性，且不会损失母体催化活性，并且为真正的环境友好方法提供了新的机会。
• IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
  申请人：Axxima Pharmaceuticals Aktiengesellschaft

  公开号：EP1532118A2

  公开（公告）日：2005-05-25
• Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections
  申请人：Salassidis Konstadinos

  公开号：US20050203155A1

  公开（公告）日：2005-09-15

  Novel imidazole compounds particularly useful against Hepatitis C Virus infections and diseases associated therewith are described. Applications of the human cellular proteins casein kinase I alpha (α), delta (δ), and epsilon (ε) as targets for medical intervention against Hepatitis C Virus (HCV) infections and diseases are also described. This invention further refers to a method for identifying compounds useful for the prophylaxis and/or treatment of Hepatitis C Virus infections and diseases, methods for treating Hepatitis C Virus infections and diseases, as well as pharmaceutical compositions useful for the prophylaxis and/or treatment of Hepatitis C Virus infections and diseases. Moreover, disclosed are antibodies, oligonucleotides and specific compounds which are effective for the detection, prophylaxis and/or treatment of Hepatitis C Virus infections and diseases. Solid supports useful for the identification of compounds suitable for preventing and/or treating Hepatitis C Virus infections and diseases are also disclosed.
• CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20200078387A1

  公开（公告）日：2020-03-12

  The present invention relates generally to chromosome maintenance and cell viability, and more specifically, to the identification of kinases the inhibition of which blocks telomere elongation. In one aspect, the present invention provides methods for treating cancer. The methods generally comprise the administration of agents that interfere with the lengthening of telomeres in cancer. In a specific embodiment, a method of treating cancer in a subject by interfering with lengthening of telomeres in cancer cells comprises administering to the cells an effective amount of an inhibitor of casein kinase 1 (CK1), wherein the administration of the inhibitor leads to progressive telomere shortening in the cancer cell, thereby treating cancer in the subject. In another embodiment, the method can further comprise administering to the cells an effective amount of an inhibitor of bromodomain-containing protein 4 (BRD4) and/or an inhibitor of the MEK/ERK pathway.
• [EN] IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS<br/>[FR] COMPOSES D'IMIDAZOLE ET PROTEINES CELLULAIRES HUMAINES CASEINE KINASE I ALPHA, DELTA ET EPSILON UTILISES COMME CIBLE LORS D'INTERVENTIONS MEDICALES CONTRE DES INFECTIONS PAR LE VIRUS DE L'HEPATITE C
  申请人：AXXIMA PHARMACEUTICALS AG

  公开号：WO2004005264A2

  公开（公告）日：2004-01-15

  The present invention describes novel imidazole compounds, which are particularly useful against Hepatitis C Virus infections and diseases associated therewith. Furthermore, the invention relates to the human cellular proteins casein kinase I alpha (α), delta (δ), and epsilon (ϵ) as targets for medical intervention against Hepatitis C Virus (HCV) infections and diseases. In addition, the present invention refers to a method for the identification of compounds which are useful for the prophylaxis and/or treatment of infections and diseases caused by Hepatitis C Virus, methods for treating Hepatitis C Virus infections and diseases, as well as pharmaceutical compositions useful for the prophylaxis and/or treatment of Hepatitis C Virus infections and diseases. Moreover, disclosed are antibodies, oligonucleotides and specific compounds which are effective for the detection, prophylaxis and/or treatment of infections and diseases caused by Hepatitis C Virus. In addition, the present invention describes solid supports useful for the identification of compounds suitable for preventing and/or treating infections and diseases caused by said Hepatitis C Virus.